Latent Autoimmune Diabetes in Adults: Current Status and New Horizons.
10.3803/EnM.2018.33.2.147
- Author:
Paolo POZZILLI
1
;
Silvia PIERALICE
Author Information
1. Department of Endocrinology & Diabetes, University Campus Bio-Medico, Rome, Italy. p.pozzilli@unicampus.it
- Publication Type:Review
- Keywords:
Islet cell;
Autoantibodies;
Diabetes mellitus, type 1;
Diabetes mellitus, type 2;
C-peptide;
B-cell function;
Insulin;
Insulin resistance;
Latent autoimmune diabetes in adults
- MeSH:
Adult*;
Autoantibodies;
C-Peptide;
Diabetes Complications;
Diabetes Mellitus, Type 1*;
Diabetes Mellitus, Type 2;
Diagnosis;
Dipeptidyl-Peptidase IV Inhibitors;
Glucagon-Like Peptide 1;
Humans;
Hypoglycemic Agents;
Insulin;
Insulin Resistance;
Islets of Langerhans;
Phenotype;
Population Characteristics
- From:Endocrinology and Metabolism
2018;33(2):147-159
- CountryRepublic of Korea
- Language:English
-
Abstract:
Autoimmune diabetes is a heterogeneous disease which can arise at any age. Subjects with adult-onset autoimmune diabetes who do not necessitate insulin-therapy for at least 6 months after diagnosis are demarcated as having latent autoimmune diabetes in adults (LADA). This condition is more heterogeneous than young-onset autoimmune diabetes and shares clinical and metabolic characteristics with both type 2 and type 1 diabetes. Patients with LADA are considered by having highly variable β-cell destruction, different degrees of insulin resistance and heterogeneous titre and pattern of islet autoantibody, suggesting different pathophysiological pathways partially explaining the heterogeneous phenotypes of LADA. To date the heterogeneity of LADA does not allow to establish a priori treatment algorithm and no specific guidelines for LADA therapy are available. These subjects are mostly treated as affected by type 2 diabetes, a factor that might lead to the progression to insulin-dependency quickly. A personalised medicine approach is necessary to attain optimal metabolic control and preserve β-cell function to decrease the risk of long-term diabetes complications. Recent data concerning the use of oral antidiabetic agents as dipeptidyl peptidase 4 inhibitors and glucagon-like peptide 1 receptor agonists indicate up-and-coming results in term of protect C-peptide levels and improving glycaemic control. This review summarises current knowledge on LADA, emphasising controversies regarding its pathophysiology and clinical features. Moreover, we discuss data available about novel therapeutic approaches that can be considered for prevention of β-cell loss in LADA.
